BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...inflammatory diseases.It’s also the Swiss pharma’s second takeout in the space in the past two years.Roche’s Genentech Inc....
...the pharma an NLRP3 inhibitor in preclinical development for inflammatory diseases, including non-alcoholic steatohepatitis (see “Genentech...
BioCentury | Sep 18, 2020
Product Development

Genentech finds right endpoint to show IL-6 benefit in COVID-19

...mechanical ventilation may be the primary benefit of IL-6 inhibition  By stephen hansen, associate editor Genentech...
...an endpoint that can tease out the benefit of IL-6 inhibitors in treating COVID-19 patients.The Genentech Inc....
...that looked for improvements in clinical status based on a seven-category ordinal scale.In late July, Genentech...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

...at BlueRock Therapeutics L.P., which Bayer AG (Xetra:BAYN) acquired. Horn spent 16 years with at Genentech Inc....
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...BlueRock Therapeutics L.P., which Bayer AG (Xetra:BAYN) acquired. Horn, who spent 16 years with the Genentech Inc....
BioCentury | Sep 11, 2020
Product Development

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

...went to the biggest and that led us to make this major alliance with Roche Genentech...
BioCentury | Sep 9, 2020
Product Development

Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview

...unit of Roche (SIX:ROG; OTCQX:RHHBY) in January 2019 after two years as CEO of its Genentech...
...thousands of small companies obviously [who] have different considerations from you know large organizations like Genentech...
BioCentury | Sep 9, 2020
Product Development

Data Bytes: Btk race in MS heats up as Roche enters Phase III

...a race that Merck KGaA led just a few years ago.Last week, fenebrutinib from the Genentech Inc....
...Beyond MS”).According to ClinicalTrials.gov, data for evobrutinib and SAR442168 are both due in 3Q23, while Genentech...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...other thyroid cancers. Roche (SIX:ROG; OTCQX:RHHBY) and Genentech Inc....
...of Year, Blueprint Readies to put Partner Genentech...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...as EMA review in NSCLC. Amanda Micklus Blueprint Medicines Corp. Genentech Inc. RASGEF1-RET...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...their de-identified data with researchers. Founded in 2014, the company counts Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc....
Items per page:
1 - 10 of 8207
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...inflammatory diseases.It’s also the Swiss pharma’s second takeout in the space in the past two years.Roche’s Genentech Inc....
...the pharma an NLRP3 inhibitor in preclinical development for inflammatory diseases, including non-alcoholic steatohepatitis (see “Genentech...
BioCentury | Sep 18, 2020
Product Development

Genentech finds right endpoint to show IL-6 benefit in COVID-19

...mechanical ventilation may be the primary benefit of IL-6 inhibition  By stephen hansen, associate editor Genentech...
...an endpoint that can tease out the benefit of IL-6 inhibitors in treating COVID-19 patients.The Genentech Inc....
...that looked for improvements in clinical status based on a seven-category ordinal scale.In late July, Genentech...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

...at BlueRock Therapeutics L.P., which Bayer AG (Xetra:BAYN) acquired. Horn spent 16 years with at Genentech Inc....
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...BlueRock Therapeutics L.P., which Bayer AG (Xetra:BAYN) acquired. Horn, who spent 16 years with the Genentech Inc....
BioCentury | Sep 11, 2020
Product Development

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

...went to the biggest and that led us to make this major alliance with Roche Genentech...
BioCentury | Sep 9, 2020
Product Development

Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview

...unit of Roche (SIX:ROG; OTCQX:RHHBY) in January 2019 after two years as CEO of its Genentech...
...thousands of small companies obviously [who] have different considerations from you know large organizations like Genentech...
BioCentury | Sep 9, 2020
Product Development

Data Bytes: Btk race in MS heats up as Roche enters Phase III

...a race that Merck KGaA led just a few years ago.Last week, fenebrutinib from the Genentech Inc....
...Beyond MS”).According to ClinicalTrials.gov, data for evobrutinib and SAR442168 are both due in 3Q23, while Genentech...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...other thyroid cancers. Roche (SIX:ROG; OTCQX:RHHBY) and Genentech Inc....
...of Year, Blueprint Readies to put Partner Genentech...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...as EMA review in NSCLC. Amanda Micklus Blueprint Medicines Corp. Genentech Inc. RASGEF1-RET...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...their de-identified data with researchers. Founded in 2014, the company counts Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc....
Items per page:
1 - 10 of 8207